All stock lists
Unlock the score
Lipocine Inc. (NASDAQ:LPCN)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.43-0.01 (-0.69%)
Market cap
$11.8M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 22, 2013
Website
Insider Score
/ 100
LPCN Insider Score
Lipocine Inc. has a live Insider Score.
Scored on 3 qualifying trades from 1 insider in the last 90 days.
Financial Health Score
Fair
From LPCN’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $1.6M
- Net income
- -$11.9M
- Net margin
- -755.1%
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $5.0M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $23.7M
- Current liabilities
- $2.1M
- Current ratio
- 11.48
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$11.2M
- Free cash flow
- -$11.2M
- FCF margin
- -713.0%
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 8.2M
- Share growth (1y)
- 53.5%
- Cash runway
- 5 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
LPCN Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 190.10 K | 119.40 K | 1.15 M | 114.57 K | 622.85 K | 93.86 K |
| Revenue Growth (YoY) | -69.48 % | 27.20 % | -67.19 % | — | 595.42 % | -98.77 % |
| Cost of Revenue | 0.00 | 14.81 K | 14.98 K | 0.00 | 2.14 M | 0.00 |
| Gross Profit | 190.10 K | 104.58 K | 1.13 M | 114.57 K | -1.51 M | 93.86 K |
| SG&A Expense | 990.96 K | 1.20 M | 983.39 K | 767.84 K | 890.43 K | 1.12 M |
| R&D Expense | 2.04 M | 2.75 M | 2.69 M | 2.71 M | 2.12 M | 1.06 M |
| Operating Expenses | 3.03 M | 3.95 M | 3.65 M | 3.48 M | 890.43 K | 2.18 M |
| Operating Income | -2.84 M | -3.85 M | -2.52 M | -3.36 M | -2.40 M | -2.09 M |
| Pretax Income | -2.62 M | -3.67 M | -2.37 M | -3.19 M | -2.21 M | -1.86 M |
| Tax Provision | 200.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00 |
| Net Income | -2.62 M | -3.67 M | -2.37 M | -3.19 M | -2.21 M | -1.86 M |
| EPS (Basic) | -0.32 | -0.54 | -0.42 | -0.59 | -0.41 | -0.35 |
| EPS (Diluted) | -0.32 | -0.54 | -0.42 | -0.59 | -0.41 | -0.35 |
| Shares Outstanding | 8.22 M | 6.79 M | 5.45 M | 5.41 M | 5.35 M | 5.35 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.